Your browser doesn't support javascript.
A Review on DNA Vaccines in Pre-Clinical Trials Against SARS-CoV-2
Journal of Experimental Biology and Agricultural Sciences ; 10(3):487-493, 2022.
Article in English | Scopus | ID: covidwho-1934786
ABSTRACT
COVID 19 Pandemic is caused by the viral pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Scientific fraternity worldwide swiftly developed various types of vaccines for the prevention and as mitigation measures for curbing the pandemic. Traditional inactivated vaccines, mRNA vaccines (protein subunits such as spike proteins), and viral vector vaccines (non-replicating vectors with protein subunits) have been approved by World Health Organisation (WHO) for emergency use. The emergence of many mutated variants has been a worrying factor in the fight against the pandemic. There has been continuous research in the quest for more therapeutics, especially vaccines to curb and stop the pandemic. According to WHO, there are 194 vaccines in pre-clinical trials belonging to various types out of which sixteen is DNA vaccines. In this review, we have discussed the advantages and disadvantages of the DNA vaccines for Covid-19. This article tried to explore the available information on DNA vaccines and their current status against Covid – 19 which are in pre-clinical trials. © 2022, Editorial board of Journal of Experimental Biology and Agricultural Sciences. All rights reserved.
Keywords

Full text: Available Collection: Databases of international organizations Database: Scopus Type of study: Prognostic study Topics: Vaccines Language: English Journal: Journal of Experimental Biology and Agricultural Sciences Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: Scopus Type of study: Prognostic study Topics: Vaccines Language: English Journal: Journal of Experimental Biology and Agricultural Sciences Year: 2022 Document Type: Article